Clinical guideline
Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
J Natl Compr Canc Netw · 2026
Studies and guidelines: Lung cancer
49 items with a structured summary · Lung cancer: the complete guide
Clinical guideline
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025
J Natl Compr Canc Netw · 2025
Clinical guideline
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer
ESMO Open · 2024
Clinical guideline
Screening for Lung Cancer
JAMA · 2021
228,820 peopleNew lung cancer diagnoses in the United States (2020, estimate)
Clinical guideline
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Annals of Oncology · 2023
Clinical trial · Phase 3
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study
Ann Oncol · 2026
64.6% vs 53.6%5-year overall survival
Other
Ivonescimab Plus Chemo Extends Squamous NSCLC Survival
Cancer Discovery · 2026
Significant improvement with ivonescimab plus chemotherapy compared with the immunotherapy–chemotherapy combinationOverall survival
Clinical trial · Phase 3
Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial
The Lancet Oncology · 2026
438 patients (219 in each group) of 660 screenedNumber of patients enrolled
Clinical trial · Phase 3
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
N Engl J Med · 2026
47.5 months vs 37.6 monthsMedian overall survival
Clinical trial · Phase 3
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
N Engl J Med · 2025
HR 0.72Overall survival (final analysis)
Clinical trial · Phase 3
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
N Engl J Med · 2024
39.1 vs 5.6 monthsMedian progression-free survival
Clinical trial · Phase 3
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
N Engl J Med · 2023
85% vs 73%5-year overall survival (stage II–IIIA)
Clinical trial · Phase 3
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
J Clin Oncol · 2023
19.4% vs 11.3%5-year overall survival
Clinical trial · Phase 2
Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer
N Engl J Med · 2022
55%Centrally confirmed objective response
Review article
Lung cancer
The Lancet · 2021
About 2 millionAnnual new cases of lung cancer worldwide
Clinical trial · Phase 3
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
N Engl J Med · 2020
38.6 months vs 31.8 monthsMedian overall survival
Clinical trial
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial
N Engl J Med · 2020
0.76Cumulative rate ratio for lung cancer death at 10 years (men)
Clinical trial · Phase 3
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
JCO · 2018
128 of 200 patients with a brain scan (osimertinib 61, standard EGFR-TKI 67)Number of patients with CNS lesions on baseline imaging
Clinical trial · Phase 3
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
N Engl J Med · 2017
10.1 months vs 4.4 monthsMedian PFS
Clinical trial · Phase 3
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
N Engl J Med · 2016
10.3 months vs 6.0 monthsMedian progression-free survival
Clinical trial
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
N Engl J Med · 2011
20.0%Relative reduction in lung cancer deaths
Clinical trial
Early palliative care for patients with metastatic non-small-cell lung cancer
N Engl J Med · 2010
98.0 vs 91.5Quality of life at 12 weeks (FACT-L)
Clinical trial · Phase 3
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
N Engl J Med · 2006
12.3 months vs 10.3 monthsMedian overall survival
Clinical trial
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
N Engl J Med · 2002
19%Response rate (all 1155 eligible patients)
Clinical trial · Phase 3
Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
N Engl J Med · 1991
40% vs 77%At least one episode of febrile neutropenia
Clinical trial · Phase 3
Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
N Engl J Med · 2024
93.8% vs 63.0%2-year DFS (stage II–IIIA)
Clinical trial · Phase 3
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
J Clin Oncol · 2024
Not reached vs 9.1 monthsMedian progression-free survival
Clinical trial · Phase 3
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
The Lancet · 2021
HR 0.66 (95% CI 0.50–0.88)Disease-free survival — stage II–IIIA with PD-L1 ≥1%
Clinical trial · Phase 3
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
N Engl J Med · 2018
8.3 vs 6.8 monthsProgression-free survival (WT population): ABCP vs BCP
Clinical trial · Phase 3
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
N Engl J Med · 2018
12.3 months vs 10.3 monthsMedian overall survival
Clinical trial · Phase 3
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
N Engl J Med · 2017
41% (62 of 152 patients) with alectinib vs 68% (102 of 151 patients) with crizotinibDisease progression or death events
Clinical trial · Phase 2
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
The Lancet Oncology · 2016
48% (95% CI 36–60)Objective response (independent review committee assessment)
Clinical trial · Phase 2
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
JCO · 2016
50%Objective response rate (ORR) by IRC
Clinical trial · Phase 3
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
Lancet · 2026
27.9 vs 23.7 monthsMedian overall survival
Other
Ivonescimab in advanced NSCLC: is progression-free survival enough, or are overall survival data also needed?
The Lancet · 2025
Clinical trial · Phase 3
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
Lancet · 2025
11.1 vs 5.8 monthsMedian progression-free survival
Clinical trial · Phase 3
Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC
N Engl J Med · 2025
0.75 (95% CI 0.61–0.92)Overall survival (hazard ratio for death)
Clinical trial · Phase 3
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
N Engl J Med · 2025
13.6 vs 8.3 monthsMedian overall survival
Clinical trial · Phase 3
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
N Engl J Med · 2024
55.9 vs 33.4 monthsMedian overall survival
Clinical trial · Phase 3
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
N Engl J Med · 2023
Stratified hazard ratio 0.68 (95% CI 0.53–0.88)Event-free survival (first interim analysis)
Clinical trial · Phase 3
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
J Clin Oncol · 2022
42.9% vs 33.4%5-year overall survival
Clinical trial · Phase 2
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
N Engl J Med · 2021
46 patients (37.1%)Objective response (primary endpoint)
Clinical trial · Phase 3
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
The Lancet · 2019
0.73 (95% CI 0.59–0.91)Hazard ratio (HR) for overall survival
Clinical trial · Phase 3
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
N Engl J Med · 2019
17.1 months vs 14.9 monthsMedian overall survival (PD-L1 ≥ 1%): nivolumab + ipilimumab vs chemotherapy
Clinical trial · Phase 3
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
The Lancet · 2025
11.1 months (95% CI 9.9 to not estimable) with ivonescimab vs 6.9 months (5.8–8.6) with tislelizumabMedian progression-free survival (PFS)
Clinical trial · Phase 3
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
N Engl J Med · 2024
23.7 vs 16.6 monthsMedian progression-free survival
Clinical trial · Phase 3
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet · 2024
71% vs 64%36-month overall survival
Clinical trial · Phase 3
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
N Engl J Med · 2023
HR 0.62Progression-free survival (investigator assessment)
Clinical trial · Phase 3
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
N Engl J Med · 2018
18.9 months vs 10.2 monthsMedian progression-free survival
Nothing found.